Medical Weight Loss
Compound Tirzepatide
Dual-action weight loss — the most advanced GLP-1 protocol available.
Overview
Compound tirzepatide is a first-in-class dual GIP/GLP-1 receptor agonist — the most advanced compound in the GLP-1 class. By activating both GIP and GLP-1 receptors simultaneously, tirzepatide produces superior weight loss outcomes compared to GLP-1 monotherapy. It is fully supervised and prescribed based on individual medical eligibility.
Administration
Weekly self-injection (you give it to yourself at home)
Frequency
Once weekly with gradual dose escalation over 4–20 weeks
Program Track
Medical Weight Loss
Pricing
from $199 /mo
Annual prepay rate · monthly billing $249/mo · all-inclusive
How It Works
How Tirzepatide Works
Tirzepatide mimics two naturally occurring gut hormones: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). Dual receptor activation produces synergistic effects on appetite suppression, insulin secretion, and fat tissue signaling — resulting in greater caloric reduction, improved insulin sensitivity, and superior body composition changes compared to GLP-1 agonists alone.
Benefits
What to expect
Eligibility
Who this program is for
Patients seeking the highest level of clinically supervised weight loss support. Eligibility is determined individually by your prescribing clinician — this program is the most medically intensive in our lineup and requires consistent monitoring and follow-up.
Clinical supervision required. Eligibility for this program is determined by your prescribing clinician based on individual medical history. Not all patients will qualify.
FAQ
Common questions
Is compound tirzepatide the same as Mounjaro or Zepbound?
Mounjaro and Zepbound are brand-name versions of tirzepatide from Eli Lilly. Compound tirzepatide uses the same active peptide formulated by a licensed 503A pharmacy. Your prescribing clinician will determine whether compounded tirzepatide is clinically appropriate for you.
How does tirzepatide compare to semaglutide?
Clinical trials show tirzepatide produces 20–22% body weight reduction vs. 15–18% with semaglutide. The dual mechanism also produces stronger improvements in insulin sensitivity. For patients with metabolic syndrome or diabetes risk, tirzepatide may be the preferred option.
What are the side effects?
Similar to semaglutide: nausea, vomiting, diarrhea, and constipation — most common during dose escalation. The gradual titration schedule is designed to minimize these effects. Rare but serious risks (pancreatitis, thyroid concerns) are reviewed with your clinician.
Ready to start your Tirzepatide program?
Complete a brief online intake — a licensed clinician will review your goals and confirm eligibility.